Search Results - "CASTAÑEDA, JAVIER"

Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users by Silva, Julien Da, Lepore, Giuseppe, Battelino, Tadej, Arrieta, Arcelia, Castañeda, Javier, Grossman, Benyamin, Shin, John, Cohen, Ohad

“…The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The…”
Get more information

Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G System by Castañeda, Javier, Arrieta, Arcelia, van den Heuvel, Tim, Battelino, Tadej, Cohen, Ohad

“…We studied time in tight range (TITR) (70-140 mg/dL) in real-world users of the MiniMed 780G system (MM780G). CareLink Personal data were extracted (August…”
Get full text

Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users by Arrieta, Arcelia, Battelino, Tadej, Scaramuzza, Andrea E., Da Silva, Julien, Castañeda, Javier, Cordero, Toni L., Shin, John, Cohen, Ohad

“…Aim To investigate real‐world glycaemic outcomes and goals achieved by users of the MiniMed 780G advanced hybrid closed loop (AHCL) system aged younger and…”
Get full text

The significance of coefficient of variation as a measure of hypoglycaemia risk and glycaemic control in real world users of the automated insulin delivery MiniMed 780G system by Castañeda, Javier, Arrieta, Arcelia, Heuvel, Tim, Cohen, Ohad

“…Aim Use of the MiniMed 780G system (MM780G) can result in a reduction in mean and standard deviation (SD) of sensor glucose (SG) values. We assessed the…”
Get full text

Predictors of time in target glucose range in real‐world users of the MiniMed 780G system by Castañeda, Javier, Mathieu, Chantal, Aanstoot, Henk‐Jan, Arrieta, Arcelia, Da Silva, Julien, Shin, John, Cohen, Ohad

“…Aim Automated insulin delivery systems have improved glycaemic control in people with type 1 diabetes mellitus. The analysis investigated predictors of…”
Get full text

Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence by Choudhary, Pratik, Arrieta, Arcelia, van den Heuvel, Tim, Castañeda, Javier, Smaniotto, Vittorino, Cohen, Ohad

“…The present report celebrates the benchmarking of 100,000 MiniMed™ 780G system users in Europe, Middle East, and Africa (EMEA) and summarizes the major…”
Get more information

Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system by Grassi, Bruno, Gómez, Ana Maria, Calliari, Luis Eduardo, Franco, Denise, Raggio, Marcela, Riera, Francisca, Castro, Matias, McVean, Jennifer, Heuvel, Tim, Arrieta, Arcelia, Castañeda, Javier, Cohen, Ohad

“…Aim We studied real‐world performance of MiniMed (MM) 780G system users from Argentina, Brazil, Colombia and Chile (geographical analysis), and the effect of…”
Get full text

Antifungal Synergy: Mechanistic Insights into the R-1-R Peptide and Bidens pilosa Extract as Potent Therapeutics against Candida spp. through Proteomics by Vargas-Casanova, Yerly, Bravo-Chaucanés, Claudia Patricia, Fuentes, Samuel de la Cámara, Martinez-Lopez, Raquel, Monteoliva, Lucía, Gil, Concha, Rivera-Monroy, Zuly Jenny, Costa, Geison Modesti, Castañeda, Javier Eduardo García, Parra-Giraldo, Claudia Marcela

“…Previous reports have demonstrated that the peptide derived from LfcinB, R-1-R, exhibits anti- activity, which is enhanced when combined with an extract from…”
Get full text

Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems by Akturk, Halis K, Battelino, Tadej, Castañeda, Javier, Arrieta, Arcelia, van den Heuvel, Tim, Cohen, Ohad

“…The concept of maintaining blood glucose levels within the 70-180 mg/dL range, known as time-in-range, has raised questions regarding its representation of…”
Get more information

Antibacterial Activity of Synthetic Peptides Derived from Lactoferricin against Escherichia coli ATCC 25922 and Enterococcus faecalis ATCC 29212 by García-Castañeda, Javier E., Rosas-Pérez, Jaiver E., Almanzar-Reina, Giovanni A., Leal-Castro, Aura L., León-Calvijo, María A., Rivera-Monroy, Zuly J.

“…Peptides derived from human and bovine lactoferricin were designed, synthesized, purified, and characterized using RP-HPLC and MALDI-TOF-MS. Specific changes…”
Get full text

Generating real‐world evidence on diabetes technology using the CareLink Personal data management system by Heuvel, Tim, Castañeda, Javier, Arrieta, Arcelia, Voelker, Benedikt, Cohen, Ohad, Liu, Margaret, Diaz Garelli, Franck, Shin, John

“…Aim To establish trust in real‐world evidence (RWE) derived from CareLink Personal (CP), Medtronic's data management system for MiniMed system users, we show…”
Get full text

Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care by Dekker, Pim, van den Heuvel, Tim, Arrieta, Arcelia, Castañeda, Javier, Mul, Dick, Veeze, Henk, Cohen, Ohad, Aanstoot, Henk-Jan

“…Complexity of glucose regulation in persons with type 1 diabetes (PWDs) necessitates increased automation of insulin delivery (AID). This study aimed to…”
Get full text

The MiniMed 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during Ramadan by Al‐Sofiani, Mohammed E., Petrovski, Goran, Al Shaikh, Abdulrahman, Alguwaihes, Abdullah, Al Harbi, Mohammad, Al Mohannadi, Dabia, Adjene, Alero, Alagha, Abdulmoeen, Al Remeithi, Sareea, Alamuddin, Naji, Arrieta, Arcelia, Castañeda, Javier, Chaar, Wael, Heuvel, Tim, Cohen, Ohad

“…Aim To report on the effectiveness and safety of the MiniMed 780G automated insulin delivery system in real‐world users during the month of Ramadan. Materials…”
Get full text

When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump by Cohen, Ohad, Filetti, Sebastiano, Castañeda, Javier, Maranghi, Marianna, Glandt, Mariela

“…Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However,…”
Get full text

Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring by van den Heuvel, Tim, Kolassa, Ralf, Keuthage, Winfried, Kroeger, Jens, Ré, Roseline, de Portu, Simona, Vorrink, Linda, Shin, John, Castañeda, Javier, Vigersky, Robert, Cohen, Ohad

“…Background: This analysis reports the findings from a predefined exploratory cohort (cohort B) from the ADAPT (ADvanced Hybrid Closed Loop Study in Adult…”
Get full text

The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery by Castañeda, Javier, Galan, Bastiaan E., Kuijk, Sander M. J., Arrieta, Arcelia, Heuvel, Tim, Cohen, Ohad

“…Aim The aim was to determine the interdependence of targets for glucose management indicator (GMI), time within the ranges of 70–180 mg/dL (TIR) and 70–140…”
Get full text

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial by Bosi, Emanuele, Choudhary, Pratik, de Valk, Harold W, Lablanche, Sandrine, Castañeda, Javier, de Portu, Simona, Da Silva, Julien, Ré, Roseline, Vorrink-de Groot, Linda, Shin, John, Kaufman, Francine R, Cohen, Ohad, Laurenzi, Andrea, Caretto, Amelia, Slatterly, David, Henderson-Wilson, Marcia, Weisnagel, S. John, Dubé, Marie-Christine, Julien, Valérie-Ève, Trevisan, Roberto, Lepore, Giuseppe, Bellante, Rosalia, Hramiak, Irene, Spaic, Tamara, Driscoll, Marsha, Borot, Sophie, Clergeot, Annie, Khiat, Lamia, Hammond, Peter, Ray, Sutapa, Dinning, Laura, Tonolo, Giancarlo, Manconi, Alberto, Ledda, Maura Serena, de Ranitz, Wendela, Silvius, Bianca, Wojtusciszyn, Anne, Farret, Anne, Vriesendorp, Titia, Immeker-de Jong, Folkje, van der Linden, Joke, Brink, Huguette S., Alkemade, Marije, Schaepelynck-Belicar, Pauline, Galie, Sébastien, Tréglia, Clémence, Benhamou, Pierre-Yves, Haddouche, Myriam, Hoogma, Roel, Leelarathna, Lalantha, Shaju, Angel, James, Linda

“…Hypoglycaemia unawareness and severe hypoglycaemia can increase fear of hypoglycaemia and the risk of subsequent hypoglycaemic events. We aimed to assess the…”
Get full text

In‐house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH‐related peptides by González‐López, Nicolás Mateo, Guerra‐Acero‐Turizo, Luisa María, Blanco‐Medina, Isabella, Barragán‐Cárdenas, Andrea Carolina, Ramírez‐Celis, David Augusto, Martínez‐Ramírez, Jorge Ariel, Fierro‐Medina, Ricardo, García‐Castañeda, Javier Eduardo, Rivera‐Monroy, Zuly Jenny

“…Abstract Matrix effect and sample pretreatment significantly affect the percentage recovery of peptides in biological matrices, affecting the method robustness…”
Get full text

Obtaining an immunoaffinity monolithic material: poly(GMA--EDMA) functionalized with an HPV-derived peptide using a thiol-maleimide reaction by Insuasty-Cepeda, Diego Sebastián, Maldonado, Mauricio, García-Castañeda, Javier Eduardo, Rivera-Monroy, Zuly Jenny

“…Metabolites have great potential for the design of biomarkers, since their presence or absence provides valuable information about a biological system. In this…”
Get full text

Evaluating the In Vitro Activity and Safety of Modified LfcinB Peptides as Potential Colon Anticancer Agents: Cell Line Studies and Insect-Based Toxicity Assessments by Cárdenas-Martínez, Karen J., Barragán-Cárdenas, Andrea C., de la Rosa-Arbeláez, Manuela, Parra-Giraldo, Claudia M., Ochoa-Zarzosa, Alejandra, Lopez-Meza, Joel E., Rivera-Monroy, Zuly J., Fierro-Medina, Ricardo, García-Castañeda, Javier E.

“…Anticancer peptides are increasingly being considered as alternative treatments for cancer due to their potency, selectivity, and low toxicity. Previously, the…”
Get full text